





Axiogenesis is an innovative biotechnology company that actively focuses on stem cell technology and molecular and cellular biology. The company's goal is to develop fast, cost-effective, and safe cell-based assays and techniques. These novel assays can be used to detect the efficacy and toxicity of new and existing drugs and chemicals on the developing embryo and differentiated functional tissue. Such inventive animal-free technologies have applications in the chemical, pharmaceutical, and cosmetic industries and provide considerable time and cost-savings in comparison to conventional in vivo systems. We welcome you to explore our website for further interesting details regarding Axiogenesis' goals, services, and products.
RNA from 100% pure Cor.At cardiomyocytes of two different maturation stages is now available. For more information please contact us. Click here!
NEW! Cor.At ready-to-use pure cardiomyocytes launched
Cor.At pure cardiomyocytes are characterized by autonomous contractility and normal electrophysiological behavior (compared to human cells). The Cor.At products cover hypertrophy analysis and differentiation of cardiac-toxicity as apoptosis, cytotoxicity and hERG interference is concerned. More ...

µEST
is an innovative in vitro embryonic stem cell (ESC) assay for evaluating the embryotoxicity and teratogenicity of drugs and other compounds. More ...
AXIOGENESIS AG
Nattermannalle 1 / S 20
50829 Cologne
Germany
info@axiogenesis.com